Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Relief Therapeutics Stock News

RLFTFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

Relief Therapeutics (RLFTF) Forecast

News

Earnings Relief Therapeutics (RLFTF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Relief Therapeutics Stock News | OTC:RLFTF | Benzinga

Get the latest news on Relief Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Relief Therapeutics performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, March 22, 2024

Eton Pharmaceuticals Acquires Exclusive U.S. ...
Benzinga Newsdesk

Monday, November 14, 2022

Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate
Vandana Singh

Thursday, July 28, 2022

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Vandana Singh

Friday, July 01, 2022

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Shanthi Rexaline

Tuesday, June 21, 2022

FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
Vandana Singh
Acer Therapeutics Says FDA Has Issued Complete Response Letter Regarding NDA For ACER-001, citing 'the need to inspect a third-party contract packaging manufacturer'; Says 'pharmacokinetics of ACER-001'
Bill Haddad

Sunday, June 05, 2022

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Shanthi Rexaline

Tuesday, May 31, 2022

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Shanthi Rexaline

Thursday, January 13, 2022

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Shanthi Rexaline
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights
Vandana Singh

Wednesday, January 12, 2022

NRx Pharma Reports Filing Of Counterclaim Aga...
Benzinga Newsdesk

Tuesday, December 14, 2021

Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Jad Malaeb - Sponsored

Wednesday, November 24, 2021

FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
Vandana Singh

Friday, November 05, 2021

NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
Vandana Singh

Wednesday, October 27, 2021

Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
Vandana Singh

Wednesday, October 06, 2021

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Shanthi Rexaline
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
Vandana Singh
Acer Therapeutics and Relief Therapeutics Announced FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders With PDUFA Target Action Date of June 5, 2022
Charles Gross

Tuesday, August 03, 2021

Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis
Vandana Singh

Friday, July 23, 2021

Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
Vandana Singh

Tuesday, June 01, 2021

NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
Vandana Singh

Monday, March 22, 2021

Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics
Vandana Singh
Relief and Acer Therapeutics Signed Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of UCDs and MSUD; , Acer to Receive ~$10M Cash Payment
Charles Gross

Monday, March 15, 2021

What's Happening With ACER Stock, MGM Stock, XPEV Stock?
Henry Khederian

Tuesday, February 09, 2021

Relief Therapeutics' COVID-19 Treatment Candidate Cuts Hospital Stay Versus Placebo, Recovery From Respiratory Failure Yet To Be Determined
Vandana Singh

Monday, January 25, 2021

Relief Therapeutics, Acer Therapeutics Signed Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease; Acer to Receive $1M Payment to Obtain Exclusivity and $4M Loan From Relief
Charles Gross

Tuesday, October 27, 2020

Traders Have Rotated Into Big Multinational Companies On OTC Markets
Spencer Israel

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved